CN1919238B - Medicine for treating cardiovascular and cerebrovascular disease - Google Patents
Medicine for treating cardiovascular and cerebrovascular disease Download PDFInfo
- Publication number
- CN1919238B CN1919238B CN2005100148372A CN200510014837A CN1919238B CN 1919238 B CN1919238 B CN 1919238B CN 2005100148372 A CN2005100148372 A CN 2005100148372A CN 200510014837 A CN200510014837 A CN 200510014837A CN 1919238 B CN1919238 B CN 1919238B
- Authority
- CN
- China
- Prior art keywords
- extract
- content
- salviae miltiorrhizae
- radix salviae
- arasaponin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 18
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 14
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims description 86
- 229940079593 drug Drugs 0.000 title claims description 20
- 239000000284 extract Substances 0.000 claims abstract description 177
- 239000000203 mixture Substances 0.000 claims abstract description 64
- 229930182490 saponin Natural products 0.000 claims abstract description 60
- 150000007949 saponins Chemical class 0.000 claims abstract description 60
- 235000017709 saponins Nutrition 0.000 claims abstract description 60
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 52
- 239000002253 acid Substances 0.000 claims abstract description 20
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 15
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 15
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 10
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims abstract description 9
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims abstract description 9
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000017276 Salvia Nutrition 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 89
- 239000009636 Huang Qi Substances 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- 239000011347 resin Substances 0.000 claims description 40
- 229920005989 resin Polymers 0.000 claims description 40
- 239000003480 eluent Substances 0.000 claims description 31
- 238000010828 elution Methods 0.000 claims description 25
- 239000006187 pill Substances 0.000 claims description 23
- 239000012567 medical material Substances 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 14
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 13
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 238000011010 flushing procedure Methods 0.000 claims description 12
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 238000002844 melting Methods 0.000 claims description 10
- 230000008018 melting Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 8
- 229940057995 liquid paraffin Drugs 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims description 6
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 claims description 6
- 108010059892 Cellulase Proteins 0.000 claims description 6
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 claims description 6
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 claims description 6
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims description 6
- 239000003957 anion exchange resin Substances 0.000 claims description 6
- 229940106157 cellulase Drugs 0.000 claims description 6
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 claims description 6
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 claims description 6
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims description 6
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims description 6
- 235000009048 phenolic acids Nutrition 0.000 claims description 6
- 150000007965 phenolic acids Chemical class 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 claims description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 5
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 5
- 241000521257 Hydrops Species 0.000 claims description 5
- 206010030113 Oedema Diseases 0.000 claims description 5
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 5
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims description 5
- 239000003456 ion exchange resin Substances 0.000 claims description 5
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 229920002545 silicone oil Polymers 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 24
- 206010008118 cerebral infarction Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 abstract description 6
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 6
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 5
- 235000005412 red sage Nutrition 0.000 abstract description 4
- 244000131316 Panax pseudoginseng Species 0.000 abstract 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 2
- 229940107666 astragalus root Drugs 0.000 abstract 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 abstract 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 abstract 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 abstract 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 239000010669 rosewood oil Substances 0.000 abstract 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000012362 glacial acetic acid Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- -1 arasaponin R1 Chemical compound 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000003657 middle cerebral artery Anatomy 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 235000012141 vanillin Nutrition 0.000 description 4
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 4
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 3
- 206010016825 Flushing Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012496 blank sample Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000053227 Themus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical group Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 101100377706 Escherichia phage T5 A2.2 gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004298 cerebral vein Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Abstract
The invention discloses a Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, which comprises astragalus root saponin extract 35.0-75%, red sage root extract 15.0-55.0%, pseudo-ginseng saponin extract 2.5-15.0%, and natural borneol or rosewood oil 2.5-15.0%. The content of danshensu in the salvia miltiorrhizae extract is 3-10%, the content of total savianolic acid is 50-75%, the content of salvianolic acid B is 20-45%, the content of total saponins in pseudo-ginseng saponin extract is 70-98%, the content of total saponins in astragalus root saponin extract is 70-98%, the content of Astragaloside IV is 5-15%. The composition has evident functions in resisting cerebral ischemia and myocardial ischemia, the curative effect is better than the application of single extract of red sage root or notoginseng saponin, thus providing a more effective and more convenient Chinese medicinal composition and preparation clinically.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof.
Background technology
According to China's Epidemiological study, though over nearly 50 years in the rural area or the city, the M ﹠ M of cardiovascular and cerebrovascular disease is all in rising trend.50～sixties, China's population cause of death central vessel disease and cerebrovascular occupied the five or six respectively, then rose to the two or three respectively later in 1975, and cardiovascular and cerebrovascular disease death person has accounted for first of whole disease cause of the death.China accounts for the percentage ratio of total dead population because of cardiovascular and cerebrovascular disease death person, rise to 42.6% of calendar year 2001 by 12.07% of nineteen fifty-seven, the person reaches 2,000,000 though die from the cardiovascular and cerebrovascular disease every year has the part patient to survive through rescue in addition, but majority stays deformity, can't take care of oneself, cause serious burden to relatives and society.Cardiovascular and cerebrovascular disease also is western countries crowd main causes of death.Infer that according to present existing epidemiologic data advancing of disease trend is: to the year two thousand twenty, the human diseases cause of the death puts in order will have great change, but coronary heart disease and apoplexy will be first and second of the human cause of the death.Till that time, estimate that global coronary heart disease death number will increase to 1,100 ten thousand from 6,300,000 of nineteen ninety; Apoplexy increases to 7,700,000 from 4,400,000.Blood circulation cause of the death formation will increase 59.6% in 30 years, and coronary heart disease and apoplexy increase 74.6% and 75% respectively.These data prove absolutely that cardiovascular and cerebrovascular disease is not only the principal disease of harm humans health, especially human " the No.1 killer " who causes death, disables at present and in following 20 years.
In the medicine of cardiovascular and cerebrovascular disease, the application of Chinese medicine and western medicine emphasizes particularly on different fields, and Chinese medicine also occupies the bigger market share with the little advantage of its side effect.In the Chinese patent medicine of present numerous treatment cardiovascular and cerebrovascular diseases, compound red sage root preparation occupies important position, is that the Chinese patent medicine of main active such as Radix Notoginseng total arasaponins, Radix Salviae Miltiorrhizae total phenolic acids, Radix Puerariae flavone, Herb Gynostemmae Pentaphylli total glycosides etc. also more and more is subject to people's attention in addition with effective site.The effect of the various effective ingredient in Chinese of treatment cardiovascular and cerebrovascular disease is had nothing in common with each other and is stressed, the great demand that has drug combination clinically, therefore, the compound red sage root preparation with the effective site preparation will have characteristics such as dosage is little, good effect, steady quality, broad market prospect.
Summary of the invention
The purpose of this invention is to provide little Chinese medicine composition efficiently of a kind of amount and preparation thereof.
Another object of the present invention provides the preparation method of said composition and preparation thereof.
The present invention is implemented by following technical proposals.
Chinese medicine composition of the present invention comprises following component by weight percentage:
Radix Astragali saponin extract 35.0%～75%,
Radix Salviae Miltiorrhizae extract 15.0%～55.0%,
Arasaponin extract 2.5%～15.0%,
Natural Broneolum Syntheticum or Lignum Dalbergiae Odoriferae oil 2.5%～15.0%;
Chinese medicine composition of the present invention more preferably comprises following component by weight percentage:
Radix Astragali saponin extract 45.0%～65.0%,
Radix Salviae Miltiorrhizae extract 25.0%～45.0%,
Arasaponin extract 5.0%～10.0%,
Natural Broneolum Syntheticum or Lignum Dalbergiae Odoriferae oil 5.0%～10.0%;
Chinese medicine composition of the present invention, best for comprising following component by weight percentage:
Radix Astragali saponin extract 54%,
Radix Salviae Miltiorrhizae extract 32%,
Arasaponin extract 7%,
Natural Broneolum Syntheticum or Lignum Dalbergiae Odoriferae oil 7%;
Radix Astragali saponin extract in the above-mentioned Chinese medicine composition, can utilize the preparation method of prior art to obtain, for example can utilize (West China pharmaceutical journals such as Chinese patent CN1096269C, Yu Hao, 1993,163), (Heilungkiang medicine, 2002,15 (5): such as Teng Xinglong 340), (Zhejiang College Of Traditional Chinese Medicine journal such as Wang Zhijie 8 (3):, 2001,25 (5): preparation method 43) is obtained Radix Astragali extract.Also can grope preparation technology voluntarily and extract Radix Astragali extract.Can also directly buy Radix Astragali extract from the market, for example content is the Radix Astragali extract of 80～98% (UV mensuration).Astragaloside content is 5%～15% in the Radix Astragali saponin extract of the present invention, and its total saponin content is 70%～98%, is preferably 80%～98%.No matter be to buy, do not reach above-mentioned content standard, then should make with extra care, make it to meet above-mentioned content standard as purity by prior art for preparing or market.
Above-mentioned Radix Salviae Miltiorrhizae extract obtains with following method: get the Radix Salviae Miltiorrhizae of salvia piece or pulverizing, decoct with water or supersound extraction 2～3 times, add 5～7 times of water gagings of medical material weight, each 0.5～2 hour at every turn; Merge extractive liquid, is 1.5～4 with acid for adjusting pH, puts coldly, filters; The resin volume is equivalent to the macroporous resin column of 2～4 times of crude drugs on the filtrate, and with 1～1.5 times of cylinder hydrops flushing, water lotion discards earlier, and 85～95% ethanol elutions of 2～3 times of column volumes of reuse are collected eluent; The eluent concentrating under reduced pressure, drying promptly gets Radix Salviae Miltiorrhizae extract.The content of Danshensu of this Radix Salviae Miltiorrhizae extract is 3%～10%, and Radix Salviae Miltiorrhizae total phenolic acids content is 50%～75%, and content of danshinolic acid B is 20%～45%.
Above-mentioned macroporous resin is the macroporous resin of nonpolar or low pole, is preferably D101, AB-8 or ZTC type macroporous resin, and the best is an AB-8 type macroporous resin.
Above-mentioned content of Danshensu assay method is referring to Chinese patent CN1520307A, and Radix Salviae Miltiorrhizae total phenolic acids assay and content of danshinolic acid B are measured referring to Chinese patent CN1600318A.
Above-mentioned arasaponin extract can obtain with following method: get the Radix Notoginseng of pulverizing, soak, transfer pH3～5.5 with acid, the amount that adds 5～15U with every gram crude drug adds cellulase, fully stirs, and puts 30～60 ℃ of water-baths 2～4 hours, and extracting solution is standby; Extracting the back residue adds water again or adds that 10%～90% alcohol heating reflux extracts or supersound extraction 1～3 time, extracting solution before and after merging; Extracting solution is evaporated to 1～3 times of amount of medical material volume, and clear liquor or filtrate are got in centrifugal or filtration; Clear liquor or filtrate are gone up anion-exchange resin column, with 40%～70% ethanol elution, collect eluent; Macroporous resin column on the eluent, first water flushing, reuse 40～70% ethanol elutions are collected ethanol elution; The eluent concentrating under reduced pressure, drying must contain the arasaponin extract of 70%～98% total saponins.Upper prop order in the above-mentioned arasaponin extract preparation method can be changed, be that the also available following method of arasaponin extract obtains: the Radix Notoginseng of getting pulverizing, soak, transfer pH3～5.5 with acid, the amount that adds 5～15U with every gram crude drug adds cellulase, fully stir, put 30～60 ℃ of water-baths 2～4 hours, extracting solution is standby; Extracting the back residue adds water again or adds that 10%～90% alcohol heating reflux extracts or supersound extraction 1～3 time, extracting solution before and after merging; Extracting solution is evaporated to 1～3 times of amount of medical material volume, and clear liquor or filtrate are got in centrifugal or filtration; Clear liquor or filtrate are gone up macroporous resin column, first water flushing, and reuse 40～70% ethanol elutions are collected ethanol elution; Anion-exchange resin column on the ethanol elution with 40%～70% ethanol elution, is collected eluent; The eluent concentrating under reduced pressure, drying must contain the arasaponin extract of 70%～98% total saponins.Arasaponin R1 content is 2%～10% in the arasaponin extract, and ginsenoside Re's content is 2%～6%, and ginsenoside Rg1's content is 15%～40%, and ginsenoside Rb1's content is 15%～40%, and ginsenoside Rd's content is 5%～12%.
Above-mentioned macroporous resin is the macroporous resin of nonpolar or low pole, is preferably D101, AB-8 or ZTC type macroporous resin, and the best is an AB-8 type macroporous resin.Above-mentioned anion exchange resin is a weak-base anion-exchange resin, and the best is a D-941 ion exchange resin.
Above-mentioned arasaponin extract content (in the ginsenoside Re) assay method is as follows:
1. instrument and reagent
1.1 instrument
Ultraviolet-uisible spectrophotometer.Chromatographic column.
1.2 standard substance, test sample and reagent
Standard substance: ginsenoside Re: Nat'l Pharmaceutical ﹠ Biological Products Control Institute
Test sample: arasaponin extract
Reagent: AB-8 macroporous resin or G..D.X-101 macroporous resin (60～80 orders, Tianjin chemical reagent two factories)
The ethanol analytical pure
Vanillin solution takes by weighing the 5g vanillin, and the ice acetic acid dissolving also is settled to 100ml.
The perchloric acid analytical pure
The glacial acetic acid analytical pure
Ginsenoside Re's standard solution: precision takes by weighing ginsenoside Re's standard substance 0.0100g, and with dissolve with methanol and be settled to 10ml, promptly every milliliter contains ginsenoside Re 1.0mg.
2. experiment
2.1 sample treatment: get the 2mg arasaponin, with certain water gaging dilution (being diluted to about 50ml).
2.2 column chromatography: make the chromatography pipe with the 10mL syringe, interior dress 4cm AB-8 macroporous resin is washed post with 20mL95% ethanol earlier, discards eluent, and reuse 25mL washes post, discards eluent.The accurate sample solution of having handled well (seeing 2.1) that adds, flow speed control is about 1mL/min.Earlier wash post with 15mL, discard eluent, reuse 20mL95% ethanol elution arasaponin is collected eluent in evaporating dish, places 75 ℃ of water-baths to volatilize.Doing colour developing with this uses.
2.3 the preparation of blank sample: in clean evaporating dish, accurately add 0.2mL5% vanillin glacial acetic acid solution, rotate evaporating dish, residue is all dissolved, add 0.8mL perchloric acid again, move into behind the mixing in the 10mL band plug graduated centrifuge tube; Add the 0.2mL glacial acetic acid in the evaporating dish again, rotate evaporating dish, make the residual liquid dissolving, move into again in the above-mentioned centrifuge tube, heat 10min in 60 ℃ of water-baths, take out, after the ice bath cooling, accurately add glacial acetic acid 5.0mL, after shaking up, promptly get blank sample.
2.4 colour developing: in the above-mentioned evaporating dish that has volatilized, accurately add 0.2mL5% vanillin glacial acetic acid solution, rotate evaporating dish, residue is all dissolved, add 0.8mL perchloric acid again, move into behind the mixing in the 10mL band plug graduated centrifuge tube; Add the 0.2mL glacial acetic acid in the evaporating dish again, rotate evaporating dish, make the residual liquid dissolving, move into again in the above-mentioned centrifuge tube, heat 10min in 60 ℃ of water-baths, take out, after the ice bath cooling, accurately add glacial acetic acid 5.0mL, after shaking up, carry out colorimetric determination (after with blank sample ultraviolet-uisible spectrophotometer being returned zero, measuring again) with standard pipe in 560nm wavelength place with the 1cm colorimetric pool.
2.5 standard pipe: draw ginsenoside Re's standard solution (1.0mg/mL) 0.1mL, with certain water gaging dilution (about 10ml), below operation rises from " A2.2 column chromatography ... ", and is identical with sample, measures absorbance.
3 calculate:
C sample=(A1 * C mark * 100)/(A2 * 6)
In the formula:
C sample: the amount of Radix Notoginseng total arasaponins (in the ginsenoside Re) in the extract, mg/100mL
A1: the absorbance of test solution,
A
2: the absorbance of titer,
C
Mark: the concentration of titer, mg/mL
Result of calculation keeps three position effective digitals.
Ginsenoside Re, ginsenoside Rd, arasaponin R1, ginsenoside Rg1, ginsenoside Rb1's content assaying method is seen Chinese patent CN1600318A in the above-mentioned arasaponin extract.
Natural Broneolum Syntheticum in the above-mentioned Chinese medicine composition should meet the Chinese Pharmacopoeia standard.Natural Broneolum Syntheticum can replace with the Borneolum Syntheticum that meets the Chinese Pharmacopoeia standard.
Lignum Dalbergiae Odoriferae oil in the above-mentioned Chinese medicine composition is that the Lignum Dalbergiae Odoriferae medical material is through the distillation gained.
Chinese medicine composition of the present invention, the various dosage forms that can be mixed and made into adjuvant on any or more than one pharmaceuticss such as starch, dextrin, lactose, microcrystalline Cellulose, hydroxypropyl methylcellulose, Polyethylene Glycol, magnesium stearate, micropowder silica gel, xylitol, lactose, glucose, glycine, mannitol, glycine etc., for example, can be made into aqueous injection, tablet, slow releasing tablet, drop pill, granule, injectable powder, capsule, microgranule.Preferred dosage form is drop pill, injectable powder.
The preparation of Chinese medicine composition composition dropping pills of the present invention: get above-mentioned Radix Astragali saponin extract, Radix Salviae Miltiorrhizae extract, arasaponin extract and natural Broneolum Syntheticum (or Lignum Dalbergiae Odoriferae oil) to scale, Polyethylene Glycol-6000 or Polyethylene Glycol-4000 or both mixture mix homogeneously with 2～4 times of medicine gross weights, heating and melting, move in the dropping-pill machine jar after changing material, in medicine liquid droplet to 6～8 ℃ liquid paraffin or the methyl-silicone oil, oil removing, promptly.
The preparation of Chinese medicine composition injectable powder of the present invention: get above-mentioned Radix Astragali saponin extract, Radix Salviae Miltiorrhizae extract, arasaponin extract and natural Broneolum Syntheticum to scale, add an amount of adjuvant and distilled water, the mixing postlyophilization, promptly.
Chinese medicine composition raw material sources of the present invention are easy to get, and are easy to industrialization; Can make various dosage forms as required, for clinical provide convenient, more effectively, the more controlled modern Chinese medicine of quality, for the patient brings more benefits, thereby produce the huge social benefit.
The present invention adopts the ferric chloride part to stick middle cerebral artery and causes the focal cerebral ischemia injury model, by mensuration, compared the treating cerebral ischemia of Chinese medicine composition of the present invention, Radix Salviae Miltiorrhizae extract, arasaponin extract to rat model nervous symptoms and cerebral infarction scope.The result shows that Chinese medicine composition of the present invention has tangible treating cerebral ischemia, and its curative effect is better than using Radix Salviae Miltiorrhizae extract or arasaponin extract separately, shows that Chinese medicine composition of the present invention has stronger synergism.
Experimental example 1 several Chinese medicine extraction compositionss are to the influence of focal cerebral ischemia in rats
(1) experiment material
1, animal
The SD rat, male, body weight 180g～200g, the quality certification number: SCXK (capital) 2002-0003 is provided by Beijing Vital River Experimental Animals Technology Co., Ltd..
2, medicine and reagent
Be subjected to reagent: the Chinese medicine composition of embodiment one, the Chinese medicine composition of embodiment two, the Radix Salviae Miltiorrhizae extract of embodiment one, the arasaponin extract of embodiment one.
Reagent: red tetrazolium (TTC) is pale yellow powder, Beijing Ma Shi fine chemicals company limited product, lot number: 011102.
3, instrument: XTT stero microscope, Yunnan Optical Instruments Factory's product; AEG-220 type electronic analytical balance, Japanese Shimadzu company product; The desk-top dentistry car of 307-6, Shanghai Dental Medical Apparatus and Instrument Factory's product; HZQ-C air bath agitator, Dongming, Harbin Medical Instruments factory product.
(2) experimental technique and result
1, grouping and administration
Laboratory animal is by the body weight random packet.Each treated animal is all in postoperative sublingual vein administration in 30 minutes, postoperative 2 hours and 23 hours intraperitoneal injection secondaries.Each medicine all is diluted to desired concn with normal saline, and injected dose adopts the 0.4ml/100g body weight.
2, the middle cerebral artery thrombus model is made
The anesthesia of rats by intraperitoneal injection 10% chloral hydrate solution (350mg/kg); right arm reclining is fixed; make a curved incision at paropia and external auditory meatus line mid point, be about 1.5cm, pinch off temporalis and excision; expose temporal bone; under stero microscope, at the bone window that cheekbone and the close oral-lateral 1mm place of temporo squamosum joint make a diameter 2.5mm, clear up residue with dental burr; expose middle cerebral artery (between tractus olfactorius and inferior cerebral vein), put small pieces plastic sheeting protection blood vessel surrounding tissue.Have the small pieces quantitative filter paper of 50% ferric chloride solution, 10 μ L to apply on this section middle cerebral artery suction, take off filter paper behind the 30min, use the normal saline flushing local organization, layer-by-layer suture steams again and raises.Room temperature is controlled at 24 ℃.
3, nervous symptoms standards of grading
To experimental animal 24h after surgery, carry out behavior and detect.Standards of grading: 1. carry the Mus tail and observe forelimb flexing situation, protract, be designated as 0 fen as two forelimb symmetries; As the offside forelimb of performing the operation shoulder flexing, elbow flexing, shoulder inward turning occur or has concurrently, is designated as 1 fen.2. animal is placed on the plane, push away both shoulders respectively, check resistance to side shifting.As bilateral resistance equity and strong, be designated as 0 fen; As operation collateral resistance is descended, be designated as 1 fen.3. animal two forelimbs are put on the wire netting, observed muscular tension.Bilateral muscular tension equity and be 0 minute effectively; Operation offside muscle of anterior limb tension force descends and is designated as 1 fen.4. carry the Mus tail, animal has ceaselessly to operation offside revolver, is designated as 1 fen.According to above standard scoring, full marks are 4 minutes, and mark is high more, and the behavior disorder of animal is serious more.
4, the mensuration of cerebral infarction scope
Behind the animal via behavior scoring, broken end is got brain.The remainder that removes behind olfactory bulb, cerebellum and the low brain stem is cut into 5 crown below 4 ℃, and (every 5ml dye liquor contains 4%TTC 1.5ml, 1M K rapidly the brain sheet to be placed the TTC dye liquor
2HPO
40.1ml all the other adding distil waters are to scale), 37 ℃ of lucifuge temperature were incubated 30 minutes, took out to be placed on the 24h that keeps in Dark Place in 10% formalin.The non-ischemic region in dyed back is a rose, and infarct is a white.White organized carefully to dig down weigh, account for the percentage ratio of full brain weight and Ipsilateral brain weight as the cerebral infarction scope with blocking tissue's weight.
5, result
Above-mentioned experimental result represents with x ± s, and relatively t check between statistical test employing group the results are shown in Table 1 and table 2.
Several Chinese medicine extract of table 1 are to the influence of MCAO rat nervous symptoms (x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with model group; Compare with the Radix Salviae Miltiorrhizae extract group,
#P＜0.05,
##P＜0.01; Compare with the arasaponin extract group,
﹠amp;P＜0.05,
﹠amp; ﹠amp;P＜0.01
Several Chinese medicine extract of table 2 are to the influence of MCAO rat cerebral infarction scope (x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with model group; Compare with the Radix Salviae Miltiorrhizae extract group,
#P＜0.05,
##P＜0.01; Compare with the arasaponin extract group,
﹠amp;P＜0.05,
﹠amp; ﹠amp;P＜0.01
The result of above table 1 and table 2 shows that each administration group all has tangible treating cerebral ischemia, and the curative effect of the present composition is best.
The present invention adopts rat experiment myocardial infarction model and external perfusion method, has compared the function of resisting myocardial ischemia of Chinese medicine composition of the present invention, Radix Salviae Miltiorrhizae extract, arasaponin extract.The result shows that Chinese medicine composition of the present invention has tangible function of resisting myocardial ischemia, and its curative effect is better than using Radix Salviae Miltiorrhizae extract or arasaponin extract separately, shows that Chinese medicine composition of the present invention has stronger synergism.
The experimentation of experimental example 2 several Chinese medicine extract function of resisting myocardial ischemia
1, grouping and administration
70 of Wister male rats, body weight 250.8 ± 24.6 is divided into 7 groups at random by body weight: the normal saline matched group; The Radix Salviae Miltiorrhizae extract group of embodiment two; The arasaponin extract group of embodiment two; Embodiment one Chinese medicine composition; Embodiment two Chinese medicine compositions.Each medicine all is diluted to desired concn with normal saline, and dosage is 4ml/kg, the tail intravenously administrable.
2, method
(1), rat experiment myocardial infarction model: animal pentobarbital sodium intraperitoneal injection of anesthesia (45mg/kg), it is fixing to face upward the position.Tracheal intubation is made the longitudinal incision of 2cm in breastbone left side, nearly breastbone side is cut off the 3rd, the 4th and reined in cartilage, open the thoracic cavity after, connect artificial respirator (ventilation 2ml/100g, 50 times/min).Cut off pericardium, expose heart, left anterior descending coronary artery root threading is in order to ligation, and record standard II lead electrocardiogram was stablized 10 minutes, and the ligation left anterior descending coronary artery is closed the thoracic cavity.With syringe sucking-off animal throat secretions, make animal recover autonomous respiration.Behind the ligation coronary artery 15min, intravenously administrable.Behind the ligation coronary artery 4 hours, win heart, 5 of the following crosscuts of ligature, carry out chlorination nitro blue tetrazolium (NBT) dyeing, calculating myocardium infarcted region area accounts for the percentage ratio of ventricle and heart area, and carries out statistical procedures (t check).
(2), stripped langendorff heart perfusion: carry out with reference to the pharmacological experimental methodology third edition.
3, result
(1), to the influence of rat experiment myocardial inyaretion scope, the results are shown in Table 3.
The various extracts of table 3 are to the influence of rat experiment myocardial inyaretion scope (x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with model group; Compare with the Radix Salviae Miltiorrhizae extract group,
#P＜0.05,
##P＜0.01; Compare with the arasaponin extract group,
﹠amp;P＜0.05,
﹠amp; ﹠amp;P＜0.01
(2), to the influence of dirty coronary flow of guinea-pig heart and heart rate, the results are shown in Table 4.
The various extracts of table 4 are to the influence of dirty coronary flow of guinea-pig heart and heart rate (x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with the Radix Salviae Miltiorrhizae extract group; Compare with the arasaponin extract group,
#P＜0.05,
##P＜0.01.
The result of above table 3 and table 4 shows that each administration group all has tangible function of resisting myocardial ischemia, and the curative effect of the present composition is best.
The specific embodiment
To be easier to understand the present invention with reference to the following example, and provide embodiment and be in order to illustrate the present invention, rather than in order to limit the scope of the invention.
Embodiment one
The preparation of Radix Salviae Miltiorrhizae extract: get the Radix Salviae Miltiorrhizae of salvia piece or pulverizing, decoct with water 2 times, add 6.5 times of water gagings of medical material weight, each 2 hours at every turn; Merge extractive liquid, is 2 with acid for adjusting pH, puts coldly, filters; The resin volume is equivalent to AB-8 type macroporous resin (production of Tianjin resin processing plant of the Nankai University) post of 3 times of crude drugs on the filtrate, and with 1.5 times of cylinder hydrops flushings, water lotion discards earlier, and 95% ethanol elution of 2.5 times of column volumes of reuse is collected eluent; Eluent is evaporated to extractum proportion 1.15, and drying under reduced pressure promptly gets Radix Salviae Miltiorrhizae extract.The content of Danshensu 4.5% of this Radix Salviae Miltiorrhizae extract, total phenolic content 57.1%, content of danshinolic acid B 27.5%.
The preparation of arasaponin extract: get notoginseng decoction piece, pulverize, add the water logging bubble of 3 times of amounts of crude drug weight, transfer pH4.0 with acid, the amount that adds 10U with every gram crude drug adds cellulase, fully stirs, and puts 40 ℃ of water-baths 3 hours, and extracting solution is standby; Extracting the back residue and add water again 90 ℃ of following reflux, extract, twice, is 7 times of water gagings of crude drug weight for the first time, is for the second time 6 times of amount crude drug weight water, and each 2 hours, extracting solution before and after merging discarded residue; Extracting solution is evaporated to 1 times of amount of medical material volume at 70 ℃, filters; The filtrate thin up is to 2 times of amounts of medical material volume, and is centrifugal, gets clear liquor; D-941 ion exchange resin on the clear liquor (the anti-resin in Shandong, Shandong subsidiary factory) post with 2.5 times of amounts of medical material volume, 50% ethanol elution, is collected eluent; Eluent is gone up AB-8 type macroporous resin (production of Tianjin resin processing plant of Nankai University) post again, with the water flushing of 4 times of amounts of medical material volume, discards earlier, and 50% ethanol elution of 4 times of amounts of reuse medical material volume is collected ethanol elution; It is 1.15 extractum that eluent is evaporated to proportion in 70 ℃, dry, get Radix Notoginseng extract, its content of the total saponins in radix notoginseng is 83.7%, arasaponin R1 content is 6.8%, and ginsenoside Re's content is 3.8%, and ginsenoside Rg1's content is 34.3%, ginsenoside Rb1's content is 30.1%, and ginsenoside Rd's content is 8.8%.
The preparation of Radix Astragali saponin extract: buy Radix Astragali extract from market, through further making with extra care (Teng Xinglong etc., Heilungkiang medicine, 2002,15 (5): 340), get the Radix Astragali saponin extract.Astragaloside content is 9.5% in this Radix Astragali saponin extract, and the content of Radix Astragali saponin is 88.9%.
Get above-mentioned Radix Astragali saponin extract 4.1g, above-mentioned Radix Salviae Miltiorrhizae extract 2.4g, above-mentioned arasaponin extract 0.5g, natural Broneolum Syntheticum 0.5g, mix homogeneously, lyophilization gets Chinese medicine composition.
Embodiment two
The preparation of Radix Salviae Miltiorrhizae extract: get the Radix Salviae Miltiorrhizae of salvia piece or pulverizing, add the water supersound extraction 2 times, add 6 times of water gagings of medical material weight, each 40 minutes at every turn; Merge extractive liquid, is 2.5 with acid for adjusting pH, puts coldly, filters; The resin volume is equivalent to D101 type macroporous resin (production of Tianjin resin processing plant of the Nankai University) post of 3 times of crude drugs on the filtrate, and with 1.0 times of cylinder hydrops flushings, water lotion discards earlier, and 95% ethanol elution of 3 times of column volumes of reuse is collected eluent; Eluent is evaporated to extractum proportion 1.15, and drying under reduced pressure promptly gets Radix Salviae Miltiorrhizae extract.The content of Danshensu 4.6% of this Radix Salviae Miltiorrhizae extract, total phenolic content 54.6%, content of danshinolic acid B 26.4%.
The preparation of arasaponin extract: get notoginseng decoction piece, pulverize, add the water logging bubble of 3.5 times of amounts of crude drug weight, transfer pH4.5 with acid, the amount that adds 12U with every gram crude drug adds cellulase, fully stirs, and puts 40 ℃ of water-baths 3 hours, and extracting solution is standby; Extracting the back residue and add 75% ethanol again 90 ℃ of following reflux, extract, twice, is 75% ethanol of 7 times of amounts of crude drug weight for the first time, is for the second time 6 times of amount 75% ethanol, and each 2 hours, extracting solution before and after merging discarded residue; Extracting solution is evaporated to 2 times of amounts of medical material volume at 70 ℃, filters; D-941 ion exchange resin on the filtrate (the anti-resin in Shandong, Shandong subsidiary factory) post with 2.5 times of amounts of medical material volume, 60% ethanol elution, is collected eluent; Eluent is gone up D101 type macroporous resin (production of Tianjin resin processing plant of Nankai University) post again, with the water flushing of 4 times of amounts of medical material volume, discards earlier, and 60% ethanol elution of 4 times of amounts of reuse medical material volume is collected ethanol elution; It is 1.15 extractum that eluent is evaporated to proportion in 70 ℃, dry, get Radix Notoginseng extract, its content of the total saponins in radix notoginseng is 81.5%, arasaponin R1 content is 6.9%, and ginsenoside Re's content is 3.4%, and ginsenoside Rg1's content is 32.2%, ginsenoside Rb1's content is 30.2%, and ginsenoside Rd's content is 8.7%.
The preparation of Radix Astragali saponin extract: with embodiment one.
Get above-mentioned Radix Astragali saponin extract 4.1g, above-mentioned Radix Salviae Miltiorrhizae extract 2.4g, above-mentioned arasaponin extract 0.5g, Lignum Dalbergiae Odoriferae oil 0.5g, add 9.0g Polyethylene Glycol-6000 mix homogeneously, fusion gets Chinese medicine composition after the cooling.
Embodiment three
The preparation of Radix Salviae Miltiorrhizae extract: get the Radix Salviae Miltiorrhizae of salvia piece or pulverizing, decoct with water 2 times, add 6.5 times of water gagings of medical material weight, each 2 hours at every turn; Merge extractive liquid, is 2 with acid for adjusting pH, puts coldly, filters; The resin volume is equivalent to ZTC type macroporous resin (production of Tianjin resin processing plant of the Nankai University) post of 3 times of crude drugs on the filtrate, and with 1.5 times of cylinder hydrops flushings, water lotion discards earlier, and 95% ethanol elution of 2.5 times of column volumes of reuse is collected eluent; Eluent is evaporated to extractum proportion 1.12, and drying under reduced pressure promptly gets Radix Salviae Miltiorrhizae extract.The content of Danshensu 4.1% of this Radix Salviae Miltiorrhizae extract, total phenolic content 53.6%, content of danshinolic acid B 24.8%.
The preparation of arasaponin extract: get notoginseng decoction piece, pulverize, add the water logging bubble of 3.5 times of amounts of crude drug weight, transfer pH4.5 with acid, the amount that adds 10U with every gram crude drug adds cellulase, fully stirs, and puts 40 ℃ of water-baths 3.5 hours, and extracting solution is standby; Extracting the back residue and add water again 90 ℃ of following supersound extraction twice, is 7 times of water gagings of crude drug weight for the first time, is 6 times of water gagings for the second time, and each 30 minutes, extracting solution before and after merging discarded residue; Extracting solution is evaporated to 2 times of amounts of medical material volume at 70 ℃, and is centrifugal; AB-8 type macroporous resin on the clear liquor (production of Tianjin resin processing plant of Nankai University) post with the water flushing of 4 times of amounts of medical material volume, discards earlier, and 65% ethanol elution of 4 times of amounts of reuse medical material volume is collected ethanol elution; Eluent is gone up D-941 ion exchange resin (the anti-resin in Shandong, Shandong subsidiary factory) post again, with 2.5 times of amounts of medical material volume, 65% ethanol elution, collects eluent; It is 1.15 extractum that eluent is evaporated to proportion in 70 ℃, dry, get Radix Notoginseng extract, its content of the total saponins in radix notoginseng is 82.9%, arasaponin R1 content is 6.2%, and ginsenoside Re's content is 3.1%, and ginsenoside Rg1's content is 33.4%, ginsenoside Rb1's content is 31.2%, and ginsenoside Rd's content is 8.9%.
The preparation of Radix Astragali saponin extract: with embodiment one.
Get above-mentioned Radix Astragali saponin extract 4.5g, above-mentioned Radix Salviae Miltiorrhizae extract 2.1g, above-mentioned arasaponin extract 0.6g, natural Broneolum Syntheticum 0.5g, mix homogeneously, lyophilization gets Chinese medicine composition.
Embodiment four
Get arasaponin extract 0.7g, the natural Broneolum Syntheticum 0.5g of Radix Salviae Miltiorrhizae extract 1.7g, embodiment two of Radix Astragali saponin extract 4.7g, the embodiment one of embodiment one, mix homogeneously, lyophilization, Chinese medicine composition.
Embodiment five
Get arasaponin extract 0.9g, the Borneolum Syntheticum 0.4g of Radix Salviae Miltiorrhizae extract 3.2g, embodiment three of Radix Astragali saponin extract 3.0g, the embodiment one of embodiment one, mix homogeneously, lyophilization, Chinese medicine composition.
Embodiment six
Get arasaponin extract 0.6g, the Lignum Dalbergiae Odoriferae oil 0.5g of Radix Salviae Miltiorrhizae extract 2.7g, embodiment two of Radix Astragali saponin extract 3.8g, the embodiment two of embodiment one, add 12.0g Polyethylene Glycol-6000 mix homogeneously, fusion, after the cooling Chinese medicine composition.
Embodiment seven
Get arasaponin extract 0.5g, the natural Broneolum Syntheticum 0.5g of Radix Salviae Miltiorrhizae extract 2.4g, embodiment one of Radix Astragali saponin extract 4.1g, the embodiment one of embodiment one, with 18.5g Polyethylene Glycol-6000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ liquid paraffin of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment eight
Get arasaponin extract 0.5g, the natural Broneolum Syntheticum 0.5g of Radix Salviae Miltiorrhizae extract 3.0g, embodiment two of Radix Astragali saponin extract 3.2g, the embodiment two of embodiment one, with 18.5g Polyethylene Glycol-4000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ liquid paraffin of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment nine
Get arasaponin extract 0.6g, the natural Broneolum Syntheticum 0.5g of Radix Salviae Miltiorrhizae extract 2.1g, embodiment one of Radix Astragali saponin extract 4.5g, the embodiment three of embodiment one, with 18.0g Polyethylene Glycol-6000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ methyl-silicone oil of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment ten
Get arasaponin extract 0.4g, the natural Broneolum Syntheticum 0.5g of Radix Salviae Miltiorrhizae extract 1.9g, embodiment two of Radix Astragali saponin extract 5.0g, the embodiment one of embodiment one, with 4.0g Polyethylene Glycol-4000 and 14.0g Polyethylene Glycol-6000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ liquid paraffin of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment 11
Get arasaponin extract 0.7g, the natural Broneolum Syntheticum 0.5g of Radix Salviae Miltiorrhizae extract 2.2g, embodiment one of Radix Astragali saponin extract 4.3g, the embodiment three of embodiment one, with 18.0g Polyethylene Glycol-6000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ liquid paraffin of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment 12
Get arasaponin extract 0.5g, the Borneolum Syntheticum 0.5g of Radix Salviae Miltiorrhizae extract 2.8g, embodiment two of Radix Astragali saponin extract 3.4g, the embodiment three of embodiment one, with 18.5g Polyethylene Glycol-6000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ liquid paraffin of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment 13
Get arasaponin extract 0.4g, the Lignum Dalbergiae Odoriferae oil 0.5g of Radix Salviae Miltiorrhizae extract 2.4g, embodiment one of Radix Astragali saponin extract 4.3g, the embodiment one of embodiment one, with 18.0g Polyethylene Glycol-6000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ methyl-silicone oil of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment 14
Get arasaponin extract 0.6g, the Lignum Dalbergiae Odoriferae oil 0.5g of Radix Salviae Miltiorrhizae extract 2.6g, embodiment two of Radix Astragali saponin extract 4.2g, the embodiment two of embodiment one, with 3.5g Polyethylene Glycol-4000 and 14.5g Polyethylene Glycol-6000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ liquid paraffin of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment 15
Get arasaponin extract 1.8g, natural Broneolum Syntheticum 1.2g, mannitol 5.5g, calcium disodium edetate 0.9g and the distilled water 1ml of Radix Salviae Miltiorrhizae extract 8.4g, embodiment one of Radix Astragali saponin extract 13.6g, the embodiment one of embodiment one, behind the said components mixing, lyophilization, 1000 of packing, promptly.
Embodiment 16
Get arasaponin extract 1.7g, natural Broneolum Syntheticum 1.2g, low molecular dextran 5.5g, calcium disodium edetate 0.9g and the distilled water 1ml of Radix Salviae Miltiorrhizae extract 6.8g, embodiment two of Radix Astragali saponin extract 15.3g, the embodiment two of embodiment one, behind the said components mixing, lyophilization, 1000 of packing, promptly.
Embodiment 17
Get arasaponin extract 2.6g, Borneolum Syntheticum 1.2g, glucose 5.5g, sodium thiosulfate 0.9g and the distilled water 1ml of Radix Salviae Miltiorrhizae extract 9.8g, embodiment one of Radix Astragali saponin extract 11.4g, the embodiment three of embodiment one, behind the said components mixing, lyophilization, 1000 of packing, promptly.
Embodiment 18
Get Lignum Dalbergiae Odoriferae oil 1.5g, join in the saturated hydroxypropyl solution of 13ml, stirring and dissolving filters, the filtrate cold drying, the clathrate powder of Lignum Dalbergiae Odoriferae oil and hydroxypropyl.Except that the clathrate powder of above-mentioned Lignum Dalbergiae Odoriferae oil and hydroxypropyl, get arasaponin extract 1.8g, mannitol 5.5g, calcium disodium edetate 0.9g and the distilled water 2ml of Radix Salviae Miltiorrhizae extract 8.2g, embodiment one of Radix Astragali saponin extract 13.5g, the embodiment one of embodiment one again, behind the said components mixing, lyophilization, 1000 of packing, promptly.
Embodiment 19
Get arasaponin extract 1.2g, the Borneolum Syntheticum 0.8g of Radix Salviae Miltiorrhizae extract 4.8g, embodiment one of Radix Astragali saponin extract 8.2g, the embodiment one of embodiment one, with 210g microcrystalline Cellulose mix homogeneously, add 3% polyvidone alcoholic solution system soft material, cross 18 mesh sieve system granules, 60 ℃ of dryings 30～45 minutes, granulate, add the 25g Pulvis Talci, mixing fills in 1000 capsules, promptly.
Embodiment 20
Get arasaponin extract 1.2g, the natural Broneolum Syntheticum 0.8g of Radix Salviae Miltiorrhizae extract 4.8g, embodiment two of Radix Astragali saponin extract 8.2g, the embodiment one of embodiment one,, be pressed into 1000, promptly with 65g microcrystalline Cellulose and 20g magnesium stearate mix homogeneously.
Claims (9)
1. Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease, form by following component by weight percentage:
Radix Astragali saponin extract 35.0%～75%,
Radix Salviae Miltiorrhizae extract 15.0%～55.0%,
Arasaponin extract 2.5%～15.0%,
Natural Broneolum Syntheticum or Lignum Dalbergiae Odoriferae oil 2.5%～15.0%;
Wherein the content of Danshensu of Radix Salviae Miltiorrhizae extract is 3%～10%, and Radix Salviae Miltiorrhizae total phenolic acids content is 50%～75%, and content of danshinolic acid B is 20%～45%; The total saponin content of arasaponin extract is 70%～98%;
The total saponin content of Radix Astragali saponin extract is 70%～98%, and Astragaloside content is 5%～15%; Described arasaponin extract is prepared by following method: get the Radix Notoginseng of pulverizing, soak, transfer pH3～5.5 with acid, the amount that adds 5～15U with every gram crude drug adds cellulase, fully stirs, and puts 30～60 ℃ of water-baths 2～4 hours, and extracting solution is standby; Extracting the back residue adds water again or adds that 10%～90% alcohol heating reflux extracts or supersound extraction 1～3 time, extracting solution before and after merging; Extracting solution is evaporated to 1～3 times of amount of medical material volume, and clear liquor or filtrate are got in centrifugal or filtration; Clear liquor or filtrate are gone up anion-exchange resin column, with 40%～70% ethanol elution, collect eluent; Macroporous resin column on the eluent, first water flushing, reuse 40～70% ethanol elutions are collected ethanol elution; The eluent concentrating under reduced pressure, drying, promptly.
2. according to the described Chinese medicine composition of claim 1, it is characterized in that the percentage by weight of described each component is:
Radix Astragali saponin extract 45.0%～65.0%,
Radix Salviae Miltiorrhizae extract 25.0%～45.0%,
Arasaponin extract 5.0%～10.0%,
Natural Broneolum Syntheticum or Lignum Dalbergiae Odoriferae oil 5.0%～10.0%;
Wherein the content of Danshensu of Radix Salviae Miltiorrhizae extract is 3%～10%, and Radix Salviae Miltiorrhizae total phenolic acids content is 50%～75%, and content of danshinolic acid B is 20%～45%; The total saponin content of arasaponin extract is 70%～98%;
The total saponin content of Radix Astragali saponin extract is 70%～98%, and Astragaloside content is 5%～15%.
3. according to the described Chinese medicine composition of claim 1, it is characterized in that the percentage by weight of described each component is:
Radix Astragali saponin extract 54%,
Radix Salviae Miltiorrhizae extract 32%,
Arasaponin extract 7%,
Natural Broneolum Syntheticum or Lignum Dalbergiae Odoriferae oil 7%;
Wherein the content of Danshensu of Radix Salviae Miltiorrhizae extract is 3%～10%, and Radix Salviae Miltiorrhizae total phenolic acids content is 50%～75%, and content of danshinolic acid B is 20%～45%; The total saponin content of arasaponin extract is 70%～98%;
The total saponin content of Radix Astragali saponin extract is 70%～98%, and Astragaloside content is 5%～15%.
4. according to the described Chinese medicine composition of the arbitrary claim of claim 1～3, it is characterized in that, arasaponin R1 content is 2%～10% in the described arasaponin extract, ginsenoside Re's content is 2%～6%, ginsenoside Rg1's content is 15%～40%, ginsenoside Rb1's content is 15%～40%, and ginsenoside Rd's content is 5%～12%, and the content of its total saponins is more than 80%.
5. according to the described Chinese medicine composition of the arbitrary claim of claim 1～3, it is characterized in that described Radix Salviae Miltiorrhizae extract is prepared by following method: get the Radix Salviae Miltiorrhizae of salvia piece or pulverizing, decoct with water or supersound extraction 2～3 times, add 5～7 times of water gagings of medical material weight, each 0.5～2 hour at every turn; Merge extractive liquid, is 1.5～4 with acid for adjusting pH, puts coldly, filters; The resin volume is equivalent to the macroporous resin column of 2～4 times of crude drugs on the filtrate, and with 1～1.5 times of cylinder hydrops flushing, water lotion discards earlier, and 85～95% ethanol elutions of 2～3 times of column volumes of reuse are collected eluent; The eluent concentrating under reduced pressure, drying, promptly.
6. Chinese medicine composition according to claim 5 is characterized in that, described macroporous resin is D101, AB-8 or ZTC type macroporous resin.
7. Chinese medicine composition according to claim 1 is characterized in that, described anion exchange resin is a D-941 ion exchange resin; Described macroporous resin is D101, AB-8 or ZTC type macroporous resin.
8. be the drop pill that active component is made according to the described Chinese medicine composition of the arbitrary claim of claim 1～3, it is characterized in that, described drop pill is prepared from by following method: get above-mentioned Radix Astragali saponin extract, Radix Salviae Miltiorrhizae extract, arasaponin extract and natural Broneolum Syntheticum or Lignum Dalbergiae Odoriferae oil to scale, Polyethylene Glycol-6000 or Polyethylene Glycol-4000 or both mixture mix homogeneously with 2～4 times of medicine gross weights, heating and melting, move in the dropping-pill machine jar after changing material, in medicine liquid droplet to 6～8 ℃ liquid paraffin or the methyl-silicone oil, oil removing, promptly.
9. be the injectable powder that active component is made according to the described Chinese medicine composition of the arbitrary claim of claim 1～3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100148372A CN1919238B (en) | 2005-08-24 | 2005-08-24 | Medicine for treating cardiovascular and cerebrovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100148372A CN1919238B (en) | 2005-08-24 | 2005-08-24 | Medicine for treating cardiovascular and cerebrovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1919238A CN1919238A (en) | 2007-02-28 |
| CN1919238B true CN1919238B (en) | 2011-10-05 |
Family
ID=37777174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005100148372A Expired - Fee Related CN1919238B (en) | 2005-08-24 | 2005-08-24 | Medicine for treating cardiovascular and cerebrovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1919238B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708240B (en) * | 2009-12-08 | 2011-08-17 | 山西医科大学 | Heard-brain benefiting dropping pills and method for preparing same |
| CN104435105B (en) * | 2013-09-25 | 2019-05-17 | 天士力医药集团股份有限公司 | One kind is by Radix Astragali, Radix Salviae Miltiorrhizae, Radix Notoginseng, the pharmaceutical composition of dalbergia wood preparation |
| CN105214048A (en) * | 2015-10-30 | 2016-01-06 | 青岛申达高新技术开发有限公司 | Be used for the treatment of the medicine of cold blood stasis type primary dysmenorrhea |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1600319A (en) * | 2003-09-23 | 2005-03-30 | 天津天士力制药股份有限公司 | Combination of Chinese traditional medicine for curing cardiovascular and cerebrovascular diseases |
| CN1626147A (en) * | 2003-12-11 | 2005-06-15 | 天津天士力制药股份有限公司 | Medication for treating coronary heart disease and angina |
| CN1628685A (en) * | 2004-09-07 | 2005-06-22 | 张平 | Medicine combination containing panax pseudo-ginseng saponin triol and preparation method thereof |
-
2005
- 2005-08-24 CN CN2005100148372A patent/CN1919238B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1600319A (en) * | 2003-09-23 | 2005-03-30 | 天津天士力制药股份有限公司 | Combination of Chinese traditional medicine for curing cardiovascular and cerebrovascular diseases |
| CN1626147A (en) * | 2003-12-11 | 2005-06-15 | 天津天士力制药股份有限公司 | Medication for treating coronary heart disease and angina |
| CN1628685A (en) * | 2004-09-07 | 2005-06-22 | 张平 | Medicine combination containing panax pseudo-ginseng saponin triol and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1919238A (en) | 2007-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100404035C (en) | Combination of Chinese traditional medicine for curing cardiovascular diseases and cerebrovascular disease | |
| CN1919248B (en) | Traditional Chinese medicinal formulation for treating cardiovascular and cerebrovascular disease | |
| JP2007505936A (en) | Pharmaceutical compositions for the treatment of cardiovascular and cerebrovascular diseases | |
| CN1919240B (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases | |
| CN100415255C (en) | Composition of Chinese traditional medicine, and preparation method | |
| CN1919238B (en) | Medicine for treating cardiovascular and cerebrovascular disease | |
| CN1919239B (en) | Traditional medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN1919252B (en) | Medicine for treating cardiovascular and cerebrovascular disease | |
| CN1919247B (en) | Chinese medicine for treating cardiovascular and cerebrovascular disease | |
| CN101313971B (en) | Chinese medicine composition for treating nephropathy | |
| CN1919242B (en) | Traditional Chinese medicine composition for treating cardiac and cerebral vascular disease | |
| CN1919249B (en) | Chinese traditional medicine for treating cardiovascular and cerebrovascular disease | |
| CN1919237B (en) | Medicine for treating cardiovascular and cerebrovascular diseases | |
| CN1919235B (en) | Cardiac and cerebral vascular disease treating pharmaceutical composition | |
| CN1919253B (en) | Cardiac and cerebral vascular disease treating medicinal composition | |
| CN1919236B (en) | Medicine for treating cardiovascular and cerebrovascular diseases | |
| CN1919244B (en) | Chinese traditional medicine for treating cardiovascular disease | |
| CN1919241B (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular disease | |
| CN1919250B (en) | Traditional Chinese medicinal formulation for treating cardiovascular and cerebrovascular disease | |
| CN1919243B (en) | Traditional medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN100584358C (en) | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method | |
| CN1919251B (en) | Traditional Chinese medicine composition for treating cardiac vascular disease | |
| CN103933386B (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
| CN106421293A (en) | Traditional Chinese medicine effective part composition for treating cardiovascular and cerebrovascular diseases | |
| CN1582946B (en) | Use of centellosic acid derivative in preparation of medicines for diseases of cardio-cerebral blood vessels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070608 Address after: Tianjin City Hedong District of Beichen Puji No. 2 in the modern Chinese medicine city Applicant after: Tianjin Tianshili Pharmaceutical Co., Ltd. Address before: The white road of Beichen science and Technology Park in Beichen District of Tianjin City Xinyi Liaohe Road No. 1 Applicant before: Tianshili Modern Traditional Chinese Medicine Research & Devleopment Co., Ltd., |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin city Beichen District Puji Hedong No. 2 in the modern Chinese medicine city Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin city Beichen District Puji Hedong No. 2 in the modern Chinese medicine city Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin city Beichen District Puji Hedong No. 2 in the modern Chinese medicine city Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin city Beichen District Puji Hedong No. 2 in the modern Chinese medicine city Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111005 Termination date: 20190824 |